Zepbound has been one of the hardest prescription medications to fill in the United States since its launch in late 2023. Explosive demand for weight loss drugs, limited manufacturing capacity, and narrow insurance coverage have all created barriers. While the supply picture has improved heading into 2025, many patients still face real obstacles getting the medication in hand.
The Supply Shortage and Where It Stands
Zepbound (tirzepatide) landed on the FDA’s official drug shortage list shortly after approval, with nearly every dose strength marked as limited availability. The starter dose of 2.5 mg was generally the easiest to find, but patients trying to fill prescriptions for the 5 mg and 7.5 mg maintenance doses reported it was extremely difficult or outright impossible at many pharmacies. Higher doses used later in treatment were similarly constrained.
The FDA formally removed tirzepatide from its drug shortage list in October 2024, then reaffirmed that decision in a December 2024 memorandum. Officially, the shortage is resolved. In practice, that doesn’t mean every pharmacy has every dose sitting on the shelf. Spot shortages at individual locations still occur because demand remains high and distribution across the pharmacy network is uneven. “Resolved” in FDA terms means the manufacturer can meet overall national demand, not that your local pharmacy will have your dose ready tomorrow.
Why Demand Outpaced Supply
The core problem is straightforward: more people wanted Zepbound than Eli Lilly could produce. Tirzepatide is a complex injectable biologic delivered through single-use pen injectors, and scaling up production of both the drug substance and the delivery device takes years, not months. Lilly has invested $1.5 billion in new manufacturing facilities, with an ambitious goal of producing medicine for patients by 2026. That timeline gives a sense of how long it takes to meaningfully expand capacity for a drug like this.
At the same time, Zepbound entered a market already strained by demand for GLP-1 medications. Patients, prescribers, and telehealth platforms all moved quickly, creating a wave of prescriptions that outstripped what any single manufacturer could fill from existing facilities.
Insurance and Cost Barriers
Even when Zepbound is physically available at a pharmacy, getting it covered is a separate challenge. Many commercial insurance plans and most Medicare Part D plans do not cover weight loss medications. Zepbound’s list price runs over $1,000 per month without insurance, which puts it out of reach for most people paying entirely out of pocket.
Some patients qualify for Lilly’s savings card program, which can reduce the cost significantly for those with eligible commercial insurance. But if your plan explicitly excludes anti-obesity medications, the savings card typically won’t apply. The result is that a large share of people who get a prescription and find it in stock still can’t afford to fill it.
What Happened With Compounded Versions
During the shortage, compounding pharmacies stepped in to fill the gap. These pharmacies produced their own versions of tirzepatide, often at a fraction of the brand-name price, which became a popular workaround for patients who couldn’t find or afford Zepbound.
Now that the FDA considers the shortage resolved, the legal landscape has shifted. Federal law generally restricts compounding pharmacies from producing copies of commercially available drugs that aren’t on the shortage list. The FDA gave compounders a wind-down period after its October 2024 decision: state-licensed pharmacies had until February 2025, and outsourcing facilities had until March 2025, to stop compounding tirzepatide under the shortage exemption. Compounders may still prepare tirzepatide in limited circumstances, such as when a prescriber documents that a specific patient needs a formulation with a meaningful difference from the commercial product. But the broad availability of cheap compounded tirzepatide that existed during the shortage has largely ended.
Practical Tips for Filling a Prescription
If you have a Zepbound prescription and your pharmacy says it’s out of stock, you have several options worth trying before giving up.
- Check other locations in the same chain. Ask your pharmacist to look up inventory at nearby stores in their network. Supply can vary dramatically between locations in the same city.
- Use your pharmacy’s app or website. Many chains let you monitor your prescription status digitally, so you’ll get a notification the moment your dose is available for pickup rather than calling repeatedly.
- Enroll in auto-refill. This puts your prescription in the queue automatically, which can help you avoid gaps. Pharmacies that expect a recurring order are more likely to keep your dose in stock.
- Try independent or specialty pharmacies. Smaller pharmacies sometimes have inventory that larger chains don’t, and specialty pharmacies that focus on injectables may have more reliable supply chains for these medications.
- Ask about mail-order options. Some insurance plans partner with mail-order pharmacies that draw from centralized distribution centers, which can be better stocked than retail locations.
The Dose Escalation Problem
One frustration specific to Zepbound is that patients start on a low dose and gradually increase over several months. You might have no trouble filling the 2.5 mg starter dose, then hit a wall when you need to step up to 5 mg or 7.5 mg. During the worst of the shortage, this pattern was widespread, with maintenance doses consistently harder to find than the introductory strength.
This creates a difficult situation. Skipping doses or bouncing between strengths isn’t ideal, and interruptions in treatment can affect both side effects and results. If you’re starting Zepbound, it’s worth planning ahead by confirming with your pharmacy that they can reliably source higher doses before you need them. Your prescriber’s office may also have insight into which local pharmacies have had the most consistent supply.
How 2025 Looks Different
The situation has genuinely improved compared to early 2024. The FDA’s removal of tirzepatide from the shortage list reflects real increases in manufacturing output, and Lilly’s ongoing investment in new production facilities signals that supply will continue expanding. The new manufacturing site is expected to come online in 2026, which should provide a more substantial buffer against future shortages.
That said, “easier than before” doesn’t mean easy. The combination of high demand, limited insurance coverage, and the wind-down of compounded alternatives means Zepbound remains harder to access than most prescription medications. For many patients, the biggest barrier has shifted from physical availability to affordability, a problem that manufacturing capacity alone won’t solve.